Adriamycin (ADR) was formulated in albumin-heparin conjugate microspheres (AHCMS) to improve site-specific delivery and to reduce the toxicity of the drug. The effect of formulating ADR in AHCMS was investigated upon intrahepatic administration to male Wag/Rij rats. After intraveno-portal (i.v.p.) administration of ADR-AHCMS, ADR peak plasma concentrations were reduced 10-fold and ADR tissue levels of non-target tissues were significantly reduced, as compared to i.v.p, administration of the free drug. At an i.v.p, administered drug dose of 7.5 mg/kg, free ADR showed distinct signs of acute toxicity. At the same dose of ADR-AHCMS, signs of toxicity were absent. Cardiac function parameters which were determined using an isolated working heart model did not change as a result of i.v.p, administration of free ADR or ADR-AHCMS at a dose of 7.5 mg/kg. Heart weights of animals in the ADR-AHCMS or the free ADR groups, however, were significantly lower than controls. Dose tolerance studies after intrahepatic-arterial (i.h.a.) administration of free ADR, empty AHCMS and ADR-AHCMS in rats demonstrated that empty AHCMS are tolerated at a dose of 45 mg/kg. Free ADR was tolerated at a dose of 4 mg/kg, whereas ADR-AHCMS were tolerated up to a dose of 10 mg ADR/kg, as indicated by the survival.
Introduction
Adriamycin (ADR) is considered to be one of the most effective antineoplastic agents currently injections, the cumulative dose should not exceed 450-550 mg/m 2 (Bielack et al., 1989) . This maximum allowable dose, however, is related to the dose schedule. Storm et al. (1989) found that reduction of cardiotoxicity induced by either continuous infusion or liposomal encapsulation of ADR is most likely related to the reduction of peak plasma levels. Moreover, it has been reported that damage to heart muscle cells is mainly related to peak ADR concentrations and that at lower concentrations higher cumulative doses are tolerated (Bielack et al., 1989) . In order to increase ADR dosages while minimising undesirable side effects albumin-heparin conjugate microspheres (AHCMS) were developed as biodegradable ion-exchange ADR carriers (Cremers et al., 1994a,b,c) . Site-specific administration of ADR should decrease peak plasma concentrations and thus decrease the exposure of healthy tissues to ADR. In this paper toxicity and pharmacokinetic studies are described which were performed using intraveno-portal (i.v.p.) administration of ADR to male Wag/Rij rats, either as a free drug or formulated in AHCMS. In addition, cardiotoxicity of free ADR and ADR-AHCMS after i.v.p, administration to rats was studied using an isolated working-heart model (Wondergem et al., 1991) . Finally, dose tolerance of free ADR and ADR-AHCMS upon intrahepatic administration via the hepatic artery (i.h.a.) was studied in healthy Wag/Rij rats.
Animals
Male Wag/Rij rats, 8-12 weeks old and weighing 260 + 40 g at the time of the experiments, were bred at the animal department of The Netherlands Cancer Institute (Amsterdam, The Netherlands) under specific pathogen-free (SPF) conditions or obtained from the Centraal Proefdieren Bedrijf (T.N.O., Rijswijk, The Netherlands). The animals were kept on a 12 h light-12 h dark cycle and fed standard rat chow and plain tap water ad libitum.
Microsphere suspensions
ADR-AHCMS were resuspended (using a minimal amount of ethanol for wetting of the microspheres) in 5% w/v glucose solution. After 2 h of rotation at 4°C in the dark, the microspheres were centrifuged and the supernatant was decanted. The ADR release in this washing solution was measured by UV/Vis spectroscopy at A494 using a Uvikon 930 spectrophotometer (Kontron Instruments, Rotkreuz, Switzerland). Fresh glucose solution was added to the microspheres to give the final concentration needed in the experiments.
ADR-plasma levels and tissue distributions after i.v.p, administration of free ADR and ADR-AHCMS in rats

Materials and methods
Materials
Albumin-heparin conjugate microspheres (AHCMS) with a diameter of 10-25 /zm (dried) were prepared by crosslinking with 0.5% glutaraldehyde as described previously (Cremers et al., 1994a) . Adriamycin • HC1 was a kind gift from Pharmachemie, Haarlem, The Netherlands. Adriamycin-loaded microspheres (ADR-AHCMS) were obtained by loading AHCMS with ADR up to a payload of 25.4% w/w as described previously (Cremers et al., 1994c) .
Surgical procedure of i.v.p, administration
Under ether anaesthesia, a midline laparotomy was performed and a loop of the small intestine was exposed. Free ADR or ADR-AHCMS (both corresponding to 5 mg ADR/kg), dissolved or resuspended in 0.5 ml 5% w/v glucose solution, was slowly injected into a mesenteric vein under microscopic observation using a 30 gauge needle. Afterwards, the vein was ligated. To increase the efficiency of the injection in the case of ADR-AHCMS, the syringe used was refilled with 0.5 ml of 5% w/v glucose solution and this was injected into another mesenteric vein. The amount of ADR injected was determined from the remainder of ADR-AHCMS in the syringe using HPLC analysis, carried out as described below.
4. Plasma pharmacokinetics and tissue distribution
Rats were anaesthetized using ether and a catheter was introduced into the ascending aorta via carotid artery cannulation. Blood samples were drawn at t = 0, 5, 15, 30, 60, 120 and 240 min after administration of free ADR or ADR-AHCMS. Blood samples were stored at -20°C until determination of the ADR content, which was performed as described below. To determine the ADR tissue distributions, rats were killed at 15, 60 and 240 min after administration of the drug. Blood samples were taken and lung, heart, intestine, spleen, kidney and liver were removed and stored at -20°C until ADR extraction and determination of the ADR content, which were performed as described below.
Adriamycin tissue extraction
Approx. 1 g of tissue was weighed into a 50 ml Falcon®tube. After addition of 1 ml of distilled water and 10 /.~1 internal standard (IS; 4-deoxydoxorubicinol) solution, the tissue was homogenized. Then, 2 ml of borate buffer (2.5 M, pH 9.2) was added. Organic phase (7 ml of CHC13/CH3OH, 4:1), was added and the mixture was vortexed for 1 min. After centrifugation (10 rain, 4000 rpm) the aqueous phase was removed. The remaining organic phase which contained IS, ADR and ADR metabolites was transferred to silanized glass vials. The solvent was evaporated at 50°C under nitrogen flow and the remainder was redissolved in 200/~1 of the HPLC mobile phase. Before injection in the HPLC system the solution was centrifuged for 20 min at 13 000 rpm. A calibration curve was determined from known amounts of ADR and IS that had been added to tissue samples from untreated rats, prior to homogenization. Calibration samples were further handled in the same way as the other samples.
HPLC analysis of ADR samples
ADR concentrations of the blood samples and the tissue extracts were determined using HPLC according to a standard procedure that was described previously (Cremers et al., 1994c) . ADR tissue levels were calculated from the calibration curve using the log ratio of the peak heights of ADR and IS. Various metabolites were detected, but they did not interfere with ADR or IS.
ADR and ADR-AHCMS cardiotoxicity in iso-
&ted working rat heart model Animals were given ADR or ADR-AHCMS i.v.p, as described above in three groups of 15 rats each. Rats of the first group were treated i.v.p, with 7.5 mg/kg of free ADR. Animals in the second group were administered i.v.p. ADR-AHCMS, corresponding to a dose of 7.5 mg of ADR/kg. The third group received no treatment and served as a control. After administration of ADR or ADR-AHCMS, rats were weighed weekly and blood samples were drawn from the tail vein every week. Haematocrit, haemoglobin content, leucocyte count, and urea and creatinine levels were determined as parameters for systemic toxicity. After 8 weeks, the animals were killed as described below. Heart, kidneys and liver were removed and after the perfusion experiment, histological slides were made. For light microscopic evaluation, tissues of heart and kidney were fixed in 4% formaldehyde and embedded in paraffin Paraclean ® and sections of 5-6 /zm were made and stained with hematoxylin and eosin (H/E).
The heart was isolated as described by Wondergem et al. (1991) . When the heart had been cooled for 30-60 s and dissected, it was lifted from the cold buffer with a blunt forceps and the aortic stump was fixed to the aortic cannula of the perfusion apparatus and after allowing the heart to recover, cardiac function was tested as described by Wondergem et al. (1991) .
Dose tolerance of ADR-AHCMS after i.h.a. admin&tration in rats
At day 0, male Wag/Rij rats were administered increasing doses of free ADR (5, 7.5, 10 mg/kg, n = 3 per group) or ADR-AHCMS (5, 7.5, 10, 15 mg ADR/kg, n = 3 per group) via the hepatic artery as described below. 12 rats (four groups, six rats each) were administered a dose of empty AHCMS, comparable with the ADR-AHCMS doses, to determine the influence of the embolization effect. Furthermore, two rats served as a control and received a sham operation and were administered 5% w/v glucose solution. Survival of the animals was followed up to 28 days and the body weights were monitored at day 0, 4, 7, 11, 14, 17, 22 and 25. Nephrotoxicity and hepatic toxicity were determined at day 14 by measurement of creatinine and urea levels, and y-glutamyl transferase (y-GT), serum glutamate oxaloacetate transaminase (SGOT), serum glutamate pyruvate transaminase (SGPT) and alkaline phosphatase (AF) levels, respectively.
6.1. Surgical procedure of i.h.a, administration
Animals were anaesthetized using 1/~l/g body weight of a mixture of 0.2 ml 2% w/v thiazine solution (Rompun ®, Bayer, Germany) and 0.8 ml 10% w/v ketamine solution (Aescoket ®, Aesculaap BV, The Netherlands), and an upper middle laparotomy was performed. Under microscopic observation, the common bile duct was dissected and a vessel loop was placed around it to be used as a tractor. Subsequently, the hepatic artery was dissected from the celiac trunk up to the confluence with the gastroduodenal artery. Then the gastroduodenal artery was isolated over 0.5 cm and a proximal and a distal 4/0 silk loop was placed. The distal one was tightened and the proximal one was pulled up in order to stretch the artery and to avoid bleeding when the artery was opened. A partial cut of the lumen of the artery was performed using microscissors and a small catheter (2 French gauge) was inserted into the gastroduodenal artery and pushed up to the hepatic artery. The catheter was maintained in its place by soft pressure with dissection forceps, meanwhile the infusion of ADR solution or empty or ADR loaded AHCMS suspension in 5% w/v glucose solution was carried out. After the infusion, the catheter was removed, the proximal ligature was tightened and the abdominal wound was closed.
Results and discussion
AHCMS and ADR-AHCMS were prepared according to standard procedures previously described by Cremers et al. (1994a,c) . ADR release from ADR-AHCMS during the washing step in the suspension procedure of the microspheres in aqueous medium was as described previously (Cremers et al., 1994c) . The amount of drug released in this washing step varied between 2 and 30% w/w of the incorporated drug depending on the batch of ADR-AHCMS used. This was taken into account in the preparation of the injections.
ADR plasma levels and tissue distributions after Lu.p. administration of free ADR and ADR-AHCMS in rats
To determine the drug targeting and controlled release efficiency of ADR-AHCMS, ADR plasma levels and tissue distributions were measured after i.v.p, injection of free drug and microsphere-formulated drug. ADR clearance from blood after administration of 5 mg ADR/kg, either as free drug or as ADR-AHCMS, is shown in Fig. 1 .
In the free ADR group the concentration of ADR in blood decreased rapidly and remained nearly constant at a low level. The initial rapid decrease in ADR concentration results from the distribution of ADR over tissues. This phase is followed by a slower elimination phase as a con- sequence of renal clearance and metabolism. This was also found by Camaggi et al. (1988) . If the drug was administered as ADR-AHCMS, a comparable profile was observed, although the drug peak levels at t = 5 min were about one-tenth of that after administration of free ADR. Overall, the blood ADR concentration of free ADR was higher than that of ADR-AHCMS, and although the same dose was given, the area under the curve (AUC) of ADR-blood is smaller in the case of ADR-AHCMS as compared with free ADR (AUCfree ADR > AUCADR-AHCMS)" This may be due to more extensive metabolism of ADR in the liver when administered as ADR-AHCMS. Intraveno-portal (i.v.p.) administration of ADR-AHCMS causes vascular occlusion whereupon ADR can be released locally (Cremers et al., 1994b) . Therefore, more ADR is present in the liver and may be metabolized more extensively. Indications for this were observed in HPLC chromatograms of liver tissue extracts (data not shown). The formation of metabolites by bioreduction of ADR was previously reported by Willmott et al. (1990) . These metabolites, however, were not analysed in this study. As already mentioned above, peak plasma levels were 10-times lower if ADR was given i.v.p, as ADR-AHCMS instead of free drug. It is therefore concluded that the use of ADR-AHCMS could prevent adverse effects related to high peak plasma levels of the drug. The ADR tissue distributions after i.v.p, administration of ADR and ADR-AHCMS at a dose of 5 mg ADR/kg are shown in Fig. 2 . The tissue levels were corrected for the amount of administered drug and differences in the extraction efficiency of IS and ADR in the various tissues. Tissue levels were also corrected for ADR present in the blood in the tissue. Fig. 2a and b shows that the ADR levels in non-target tissues upon administration of ADR-AHCMS were lower than those after injection of free ADR. The ADR levels in the liver in the free drug group remained constant at approx. 15-20/zg/g for 240 min. In the ADR-AHCMS group, however, the initial ADR level was much higher (37/zg/g), and decreased to a level 4-times lower (4.5/zg/g) than that of the free drug group at t = 240 rain. The larger decline of the ADR content in the liver may also be explained by the enhanced metabolism, due to increased bioreduction. It should be taken into account, however, that the initially higher drug content, measured in liver tissue after ADR-AHCMS administration, may be a consequence of ADR present in AHCMS lodged in the liver, which had not been released at that time. Nevertheless, whether the drug is present in the tissue itself or is still entrapped in microspheres in the tissue, it may be concluded that targeting of the drug to the liver using AHCMS is effective, since initially higher drug levels are achieved while minimising non-target e., tissue levels. Moreover, the reduction of ADR heart levels which are approx. 5-times lower if the drug is administered in microspheres, is most important considering the cardiotoxicity of the drug. The increased targeting efficiency by formulation of the drug in AHCMS is thus demonstrated by the ratios of ADR in liver and heart tissue, shown in Fig. 3 . The increased liver to heart ratios, after administration of ADR-AHCMS, indicate improved site-specific drug delivery.
ADR and ADR-AHCMS cardiotoxicity in isolated working rat heart model
General toxicity of ADR after i.v.p, administration as free drug or as microsphere-formulated drug was studied in Wag/Rij rats. In the first group (n --15), the rats were administered a dose of 7.5 mg ADR/kg, as a free drug. Due to high injection efficiency in the case of ADR-AHCMS, rats of the second group (n = 15) were administered 8.0 mg ADR/kg as a microsphere formulation. The third group (n = 15) served as a control group and was not treated. Two animals, one in each treatment group, died within 24 h after injection. During the experiment, six more animals in the free drug treated group died. In both treatment groups the body weight of the animals decreased as compared to the control animals. In the case of the ADR-AHCMS treated animals there seemed to be some recovery from the initial toxicity, since these animals started to gain weight again from 2 weeks on, whereas the free drug treated group continued losing weight during the experiment. Differences between the three groups were significant (p < 0.05).
In the free drug treated group, the haematocrit and the haemoglobin content decreased immediately compared with the controls, whereas no differences were observed between the controis and the ADR-AHCMS treated group. The leucocyte count in the free ADR group at 1 week post-administration was only 30% of that of the controls. In the ADR-AHCMS treated group the leucocyte count was initially 70% of that of the controls, but was restored after approx. 4 weeks. This is in agreement with the results of Codde et al. (1990) which reported leucopenia following intra-arterial and intravenous administration of free ADR, whereas administration of ADR bound to sulphonated polystyrene microspheres did not significantly reduce the white blood cell count.
Already 1 week post treatment, measurements of haematological parameters (leucocyte count, haematocrit, haemoglobin, urea and creatinine content) became impossible in the free ADR treated group. Blood coagulated despite the heparin. The serum was also turbid, which was ascribed to hyperlipidaemia as could be shown by centrifugation of the serum. Bizzi et al. (1983) reported hyperlipidaemia in male CD-COBS rats 14-21 days after administration of a single dose of ADR (7.5 mg/kg), resulting from a developing nephrotic syndrome. The rats in the free ADR treated group also had diarrhoea and ascites. Renal damage in this group was indicated by urea and creatinine levels which increased within 1 week, whereas the urea and creatinine levels in the control group and the ADR-AHCMS treated group remained at a constant level. 8 weeks after treatment, kidneys were removed and histological examination showed severe damage of the kidneys in the free ADR treated groups. In the kidneys of this group, vacuoles in the glomeruli, glomerular sclerosis, tubular dilatation, dense protein casts and interstitial fibrosis with cell infiltration were observed. No differences were observed between kidneys of the ADR-AHCMS treated group and the controls (data not shown). Nephrotic syndrome was probably the main cause of death in the animals in the free ADR treated group. This agrees with reports of Storm et al. (1989) who concluded that ADR-induced nephropathy represents an important cause of death in experimental animals.
The cardiotoxicity of ADR and ADR-AHCMS was evaluated using an isolated working heart model. In Table 1 several cardiac performance parameters, together with the body and heart weight of the animals in the different treatment groups are presented. Table 1 shows that no significant differences in the cardiac performance parameters were found. At histological examination, prominent histopathological differences between the three groups were absent. In both drug treated groups, however, some fibrillar loss was observed. Macroscopically, the hearts from the free drug treated group seemed somewhat flabby in comparison with hearts in the other groups and the left ventricular wall of these hearts was thinner than that of the two other groups.
Although heart weights were significantly decreased in ADR treated animals in both treatment groups and some heart damage was observed on a microscopic level in the free drug treated group, no significant changes in cardiac function were measured. It has been reported that morphological and histological changes do not always correlate with loss of cardiac function. lsner et al. (1983) found that 35% of patients with impaired left ventricular systolic performance had no light microscopic histological signs of toxicity, whereas in 52% of the patients without clinical toxicity, histological abnormalities were present. Reeves et al. (1990) suggested that the prediction and quantitation of ADR cardiotoxicity based on light microscopic changes is uncertain. An explanation for lack of functional impairment may be that both peak plasma levels and cumulative doses are important factors in the development of cardiac disfunction. Iatropolous (1984) reported that the earliest evidence for ADR associated cardiomyopathy was morphological, followed by clinical signs after two to five additional doses. Cummings and Smyth (1988) reported that ADR-induced cardiotoxicity has been more closely linked with repeated drug treatment. Yeung et al. (1989) , however, studied changes in cardiac function in Sprague Dawley rats after a single intravenous ADR injection of 1-4 mg/kg. There was an initial phase of rapid decline in cardiac output in the first 12 weeks and a second phase of persistent depression in cardiac function. These data suggest that strain differences may play an important role in the development of cardiomyopathy. This was also reported by Jaenke and Fajardo (1977) who found species and strain related variations in toxicity of anthracyclines in kidney and heart.
Since in rats the chronic toxicity of ADR not only includes cardiotoxicity but also nephrotoxicity, the question was raised whether nephrotoxicity adds to or even might be responsible for ADR-induced cardiotoxicity in rats, in fact it was suggested by Van der Vijgh et al. (1978) that Table 1 Cardiac performance and body and heart weights a of ADR-treated animals measured in an isolated working heart model at a left atrial filling pressure of 15 cmH20 and at an aortic pressure of 90 cmH20 Cremers et al. ~International Journal of Pharmaceutics 120 (1995) 51-61 cardiotoxicity of ADR in rats is partly related to concomitant nephrotoxicity. In our study, however, nephrotoxicity was evident without loss of cardiac function. In a study of Van Hoesel et al. (1986) it was concluded that cardiomyopathy observed in Lou/M rats is a simultaneous phenomenon independent of nephropathy. From the initial decrease in body weights of treated animals, it can be concluded that, at an ADR dose of 7.5 mg/kg, the drug is toxic to the animals. ADR-AHCMS treated animals started gaining weight again whereas free drug treated animals continued losing weight, demonstrating reduced toxicity of the microsphere formulated drug. The same trend was observed from the survival of the animals, seven animals in the free drug treated group died whereas in the ADR-AHCMS group only one animal died. From the evaluation of the haematological parameters it was also concluded that the ADR-AHCMS was less toxic than free ADR. In the latter group leucocyte count, haemoglobin content and haematocrit was significantly decreased, whereas there was no difference between the ADR-AHCMS treated animals and the controls, except for a transient small decrease in the leucocyte count, as far as these parameters are concerned. Nephrotoxicity was manifest in the free ADR treated group, while there was no change in renal function and kidney histology in ADR-AHCMS treated animals and controls. Overall, these results suggest that the toxicity of the drug is reduced when formulated in AHCMS.
Dose tolerance of ADR-AHCMS after i.h.a. administration in rats
Administration of ADR-AHCMS into the hepatic artery (i.h.a.) of Wag/Rij rats was more difficult than i.v.p, administration. The i.h.a, administration was carried out by injection into a small-diameter catheter. Injecting ADR solutions was no problem. Injection of ADR-loaded or empty AHCMS was more difficult, because the catheter was sometimes occluded by the microspheres and it was laborious to empty the syringe completely. This is reflected in Table 2 by the differences between the planned dose and the administered dose. In the case of empty AHCMS, 61-100% of the particles was injected, whereas in the case of ADR-AHCMS only 45-52% was injected. ADR-AHCMS tended to aggregate and to stick to the wall of the syringe, a problem which was not observed with empty AHCMS. Table 2 also shows that the administration of microspheres was not very reproducible, which is indicated by the standard deviation (SD) of the means. Fig. 4 demonstrates the survival of individual animals as a function of the administered doses of ADR. Fig. 4 shows that administrations of ADR-AHCMS up to a level of 10 mg ADR/kg are tolerated, even though two rats died at lower doses (cause unknown). For free drug there is a distinct decrease in survival times with increasing drug dose, although individual differences are obvious. From Fig. 4 the maximum allowable dose of free ADR is estimated to be approx. 4 mg/kg. The differences in the dose tolerance of the ADR-formulations was also indicated by the changes of the average body weights of the animals in each group. The animals treated with the free drug lost weight, indicative of severe toxicity, with most animals dying within 20 days. One animal treated at the lowest dose of free ADR (ADR-1), survived and recovered, which was indicated by the weight gain of this animal. Animals treated with empty microspheres at any dose grew at the same rate as the control animals. The animals treated with the ADR-AHCMS initially lost weight, but after approx. 5 days the animals seemed to recover and gained weight again.
From the biochemical determination listed in Table 3 it can be seen that in the lowest free ADR group (ADR-1), there is a very mild change of the renal function, indicated by a small increase in urea levels, while creatinine levels are maintained at a normal level. In the 7.5 mg/kg group (ADR-2), there was only one animal alive at the time of the biochemical determination, and its values showed a greater change in the renal function. In most of the animals in the free drug group, there was a decrease in the alkaline phosphatase (AF) levels which is difficult to explain.
The biochemical determinations of most animals in the empty AHCMS groups, were normal at all doses, but sometimes a mild change of the renal function was detected, which could not be correlated with the dose. No changes in the hepatic function were observed in any AHCMS group. In the ADR-AHCMS groups there is a progressive deterioration in renal function which was correlated with the increase in dosage of ADR-AHCMS. No alterations of the hepatic function were detected in this group, which is in agreement with the results previously reported by Cremers et al. (1994b) .
Overall, survival, body weights, and l~idney and liver parameters of Wag/Rij rats, after i.h.a, ad- Table 3 Kidney and liver parameters of male Wag/Rij rats, 14 days after i.h.a, administration of ADR, empty AHCMS or ADR-AHCMS
